Video Series

Experts examine decision-makers in treatment selection and navigate challenges in organizing multidisciplinary team meetings, from institutional to wider practice perspectives.

Specialists discuss adverse reactions to immunotherapy and explore the importance of CTLA-4 inhibitors in mNSCLC treatment.

Professionals deliberate the progression of Immuno-Oncology combinations while also engaging in conversations regarding the issue of immunotherapy resistance.

A panel of experts review what an effective multidisciplinary approach for NSCLC management looks like and subspecialties included in multidisciplinary teams.

The current treatment landscape for CKD patients with preexisting comorbidities is explored.

Dr Nicholas highlights key objectives in developing CKD treatment strategies.

An overview of the importance of specialty pharmacies, coupons, and product samples.

A discussion on advocating for patients to payers over high-cost drugs and generic drugs.

Dr. Gerd examines the clinical choices involved in the management of PV, following the directives of NCCN guidelines.

Dr Gerds explores similarities and differences in symptomatic patients compared to asymptomatic patients with PV.

Experts examine primary and acquired resistance mechanisms in immunotherapy, while promoting realistic treatment strategies.

Experts explore the utilization of next-generation sequencing, including liquid biopsies, in mNSCLC Diagnosis.

In their closing thoughts the panelists discuss reimbursement-related considerations surrounding mAbs.

Clinical and financial considerations surrounding screening and early intervention for CKD are discussed by key opinion leaders.

The screening process for CKD is discussed by Susanne Nicholas, MD, MPH, PhD.

A conversation on barriers which prevent patients from obtaining medications; including cost, co-pays, and prior authorization.

An overview of the combination therapy of clindamycin, benzoyl peroxide, and adapalene.

John L. Marshall M.D., explains the importance of in-person conferences and the future of AI in the field.

Risk factors for developing polycythemia vera (PV) are discussed by Aaron Gerds, MD, MS.

Experts share insights on the use chemotherapy and immunotherapy in driver-negative patients, along with the use of PD-L1 inhibitors.

Experts discuss the significance of treatment selection in patients with driver mutations.

RSV diagnosis can lead to an array of financial complications.

A panel of medical experts begin a discussion addressing the incidence and prevalence of chronic kidney disease (CKD).

Dr Haumschild drives a conversation regarding CKD treatment in the presence comorbidities such as cardiovascular disease and type 2 diabetes.

The LEAP-017 trial results presented at ESMO GI 2023 are explored by Dr Marshall.

Discussion on treatment algorithms as well as the impact of sebum in acne patients.

An overview on adverse effects for topical clascoterone, minocycline, and trifarotene

The panel provides their closing thoughts as they examine the stigmas and unmet needs surrounding schizophrenia.

Future therapies for the treatment of schizophrenia are explored by a panel of key opinion leaders.

Preemptive treatment strategies for pediatric RSV are discussed by key opinion leaders.